NOTIFICATION

Addendum

The following communication, dated 1 October 2024, is being circulated at the request of the delegation of Brazil.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Title:** Resolution – RDC number 620, 09 March 2022

|  |
| --- |
| **Reason for Addendum:** |
| [ ] | Comment period changed - date:  |
| [ ] | Notified measure adopted - date:  |
| [ ] | Notified measure published - date:  |
| [ ] | Notified measure enters into force - date:  |
| [ ] | Text of final measure available from[[1]](#footnote-1):  |
| [X] | Notified measure withdrawn or revoked - date: 24 September 2024Relevant symbol if measure re-notified:  |
| [ ] | Content or scope of notified measure changed and text available from1: New deadline for comments (if applicable):  |
| [ ] | Interpretive guidance issued and text available from1:  |
| [ ] | Other:  |

**Description:** Resolution – RDC number 620, 09 March 2022 - previously notified through G/TBT/N/BRA/1324 - which contains provisions on the Certification of Good Practices for conducting Bioavailability/Bioequivalence studies of medicaments and defines which Bioavailability/Bioequivalence studies of medicines must be carried out in certified research centers, was revoked by Resolution 926, 20 September 2024.

The final text is available only in Portuguese and can be downloaded at:

<https://antigo.anvisa.gov.br/documents/10181/6874029/RDC_926_2024_.pdf/448b8051-83fd-4b61-a18a-2351d5db9e36>

**\_\_\_\_\_\_\_\_\_\_**

1. This information can be provided by including a website address, a pdf attachment, or other information on where the text of the final/modified measure and/or interpretive guidance can be obtained. [↑](#footnote-ref-1)